Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LGND with free AI briefings, catalyst countdowns, and dilution alerts.

LGND · LIGAND PHARMACEUTICALS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$447.4M Cash on Hand
751.3mo Cash Runway
Follow LGND by email Get an email when LGND reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LGND, unsubscribe in one click. Privacy

📣 What LGND Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Denileukin Diftitox Lymphoma, T-Cell, Cutaneous Phase 4 · NCT00211198 Completed
Lasofoxifene Osteoporosis Phase 3 · NCT00141323 Completed
Raloxifene Osteoporosis Phase 3 · NCT00163137 Completed
MB07811 Hypercholesterolemia Phase 2 · NCT00879112 Withdrawn
MB07803 Type 2 Diabetes Mellitus Phase 2 · NCT00458016 Completed
Cytarabine Monophosphate Prodrug MB07133 Hepatocellular Carcinoma Phase 1/2 · NCT00073736 Completed
Sparsentan (PS433540) Hypertension Phase 2 · NCT00522925 Completed
LGD-6972 Type 2 Diabetes Mellitus Phase 2 · NCT02851849 Completed
Aplindore Early Stage Parkinson's Disease Phase 2 · NCT00623324 Completed
Bexarotene 1% gel Parapsoriasis Phase 2 · NCT00322296 Terminated
Azelastine Seasonal Allergic Rhinitis Phase 2 · NCT00940953 Completed
CE-Iohexol Contrast-induced Nephropathy Phase 2 · NCT04627831 Withdrawn
Tritace® tablet 10 mg Bioequivalence Phase 1 · NCT05438316 Completed
Tenofovir Alafenamide Chronic Hepatitis B Phase 1 · NCT04629976 Completed
Hydrochlorothiazide Bioequivalence Phase 1 · NCT05685277 Completed
Tritace® Plus tablet 10 mg/25 mg Bioequivalence Phase 1 · NCT05685277 Completed

Also used in these trials (approved or third-party drugs, not LGND's own candidates): Erlotinib Hydrochloride, Bexarotene, Carbamazepine, Budesonide, Dexamethasone, Alitretinoin, Iohexol, Irbesartan, Gefitinib, Ramipril.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LGND holds $447.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.8M/quarter from operations, an estimated runway of 751.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LGND files for a raise →

👥 Who Owns LGND

Insiders 2.4% Other 5%+ holders 25.9% Institutions (575 holders) 71.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Ligand Pharmaceuticals Incorporated 5%+ holder (13D) 5,189,177 25.94% 2026-10-30
Invesco Ltd. Institution (13G, 5%+) 1,520,911 7.60% 2026-09-30
Vanguard Portfolio Management Institution (13G, 5%+) 1,109,154 5.54% 2026-03-31
Vanguard Capital Management Institution (13G, 5%+) 997,637 4.99% 2026-03-31
Todd C Davis
Chief Executive Officer, Director · +50,058 options
Insider 199,513 1.00% 2026-06-30
Jason Aryeh
Director · +2,938 options
Insider 113,476 0.57% 2026-11-10
John W Kozarich
Director · +2,938 options
Insider 42,122 0.21% 2026-11-12
Stephen L Sabba
Director · +2,938 options
Insider 33,629 0.17% 2026-06-16
Andrew Reardon
CLO & Secretary · +45,629 options
Insider 31,854 0.16% 2026-11-02
Octavio Espinoza
Chief Financial Officer · +40,934 options
Insider 27,696 0.14% 2026-08-12
John L Lamattina
Director · +2,938 options
Insider 26,969 0.13% 2026-06-10
Nancy Ryan Gray
Director · +2,938 options
Insider 8,930 0.04% 2026-06-05

Share count 20,002,986 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LGND picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LGND and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.